Feature | May 15, 2012

The Offbeat: Saving Heart Attack Victims With Snake Venom

Peptide in green mamba snake venom may preserve cardiac and renal function following cardiac events

Nile Therapeutics is developing a peptide derived from the venom of the green mamba snake as a 90-day, out-patient treatment to prevent hospital readmissions following acute decompensated heart failure events.

 

The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), recently awarded a $2.5 million grant to Mayo Clinic’s Cardiorenal Research Laboratory to see if snake venom can improve outcomes of heart attack and heart failure patients.

The innovative research project, “Cardiovascular Peptides and Myocardial Infarction,” seeks to further understand the potential of a novel, engineered guanylyl cyclase (GC) activator, cenderitide, to reduce the level of cardiac and renal injury following a myocardial infarction, or heart attack. Researchers will try to determine whether the therapy could help prevent deterioration of cardiac and renal function following a heart attack, and potentially reduce further progression of  heart failure in patients. 

Mayo researchers invented cenderitide to activate two different subtypes of GC receptors, which uniquely differentiates cenderitide from other GC stimulating peptides. Cenderitide, a designer peptide derived from the venom of the green mamba snake, may aid in the preservation of cardiac and renal function following serious cardiovascular events, such as heart attack and acute decompensated heart failure. 

At the annual meeting of the American Heart Association in November 2011, Fernando Martin, M.D., a research fellow in the Cardiorenal Research Laboratory at Mayo Clinic, presented key research data demonstrating the ability of cenderitide to prevent the death of heart cells. 

The NHLBI grant will support basic research in the laboratory and a small proof-of-concept clinical study. Mayo plans to enroll 60 patients into the study at Mayo Clinic sites in Rochester, Minn., and Jacksonville, Fla. The endpoints of the study include safety, 30-day cardiac function, circulating hormones levels and other cardiorenal biomarkers. To learn more about the clinical study, physicians can call 507.284.4838. 

Mayo licensed cenderitide to Nile Therapeutics Inc., a biopharmaceutical company based in California. Nile is currently developing the peptide as a 90-day, outpatient treatment to prevent hospital readmissions following acute decompensated heart failure events in a study which has received a fast track investigational new drug approval from the U.S. Food and Drug Administration.

Related Content

iFR, iFR vs. FFR, ACC late breaking trial, iFR-SWEDEHEART, DEFINE-FLAIR, Justin E. Davies,

Matthias Götberg, principal investigator for the iFR-SWEDEHEART study, and Justin E. Davies, lead investigator for the DEFINE-FLAIR trial, share key points of their study with DAIC editor Dave Fornell at ACC.17. The trials showed iFR is equal in outcomes to FFR in assessing coronary lesions. 

Feature | FFR Catheters| March 20, 2017
March 20, 2017 — For patients experiencing angina (chest pain) or a heart attack, instantaneous wave-free ratio (iFR)
Sponsored Content | Videos | HIMSS| March 10, 2017
ITN Editor Dave Fornell takes a tour of some of the most innovative new technology that was displayed on the expo flo
interventional cardiology, cath lab videos
Feature | Cath Lab| March 07, 2017
Here is a compilation of some of DAIC's recent video coverage of new interventional cardiology device techno
Sponsored Content | Videos | 3-D Printing| February 09, 2017
When a pediatric patient at Children’s Hospital Los Angeles needed a custom-build stent to repair his pulmonary arter
Arterys, Cardiac MRI, cardiac MRI advances

An example of the Arterys blood flow imaging assessment software that can help automate cardiac MRI. 

Feature | Cardiac Imaging| January 16, 2017 | Dave Fornell
Each year imaging system manufacturers use the Radiological Society of North America (RSNA) meeting at the end of the
Sponsored Content | Videos | Cardiovascular Ultrasound| January 13, 2017
Detailed imaging is needed to support complex interventions for the assessment and procedure guidance.
Siemens artis pheno angiography system
Technology | Angiography| January 04, 2017
January 4, 2015 — At RSNA 2016, Siemens Healthineers unveiled its 510(k)-pending robot-supported Artis pheno angiogra
Sponsored Content | Videos | Angiography| December 07, 2016
Shimadzu's latest generation interventional lab angiography imaging system, the Trinias, enables advanced imaging cap
Siemens Healthineers, PURE Platform, angiography, EVAR, CTO, RSNA 2016
News | Angiography| December 07, 2016
December 7, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
Sponsored Content | Videos | Robotic Systems| November 22, 2016
Corindus Vascular Robotics received U.S.
Overlay Init